

# Contents

---

List of Contributors	xxvi
Foreword	xxvii
Preface	xxviii
Acknowledgements	xxix

## **SECTION 1** The Patient **1**

---

Section Introduction, 1

## **1** The Consultation **3**

---

*Frank Coffey and Dianne Bowskill*

The Consultation, 4

Elements of a Consultation, 4

(A) Preparing for the Consultation and Setting Goals, 5

(B) Establishing the Initial Rapport, 5

(C) to (G) History Taking/Diagnosis Hypothesis, 5

The Traditional Medical History, 6

Presenting Complaint (PC), 6

History of the Presenting Complaint (HxPC), 6

Past Medical and Surgical History (PMHx), 7

Family History (FamHx), 7

Medications, Drug History and Allergies, 7

Personal and Social History, 8

Systems Review, 8

(H) Physical Examination/Near-Patient Tests, 8

(I) to (K) Diagnosis, 8

Symptom Versus Disease/Condition, 10

(L) Treatment, 10

(M) To (P) Summarising and Closing the Consultation, 10

(Q) and (R) Recording and Presentation of Consultation Findings, 11

‘Bottom Liners’ When Prescribing, 11

Future Advances in Consultation, 12

Summary, 12

Activity,	13
References,	13
Further Reading,	13
Websites,	13

## 2 Accountability and Prescribing

14

*Matthew Boyd, Stephanie Bridges, and Helen Boardman*

Defining Accountability,	15
Assuring Quality,	15
Clinical Governance,	16
The Five Spheres of Accountability,	16
Professional Accountability,	16
Accountability to Your Patient,	17
Accountability to the Public/Society,	18
Accountability to the Employer,	18
Accountability to Self,	19
Using the Five Spheres of Accountability,	19
The Process of Accountable Practice,	19
Accountable Prescribing,	20
Conclusion,	20
Summary,	20
Activity,	21
References,	21
Further Reading,	22
Useful Websites,	22

## 3 Prescribing and the Law

23

*Richard Griffith*

Introduction,	23
Professionalism,	24
Authority to Prescribe,	25
Requirements for a Lawful Prescription,	26
Supplying a Prescription-only Medicine without a Prescription,	26
Patient Specific Directions,	27
Prescribing Controlled Drugs from Schedules 2–5 by Independent Nurse and Pharmacist Prescribers,	28
Authority to Compound Medicines,	28
Prescribing Controlled Drugs by other Independent Prescribers,	29
Standard of Prescribing,	29

Prescriber's Duty of Care,	30
Respecting Patient Autonomy,	30
The Propriety of Treatment,	30
Elements of a Real Consent,	30
Full Consent,	31
Freely Given Consent,	31
Reasonably Informed Consent,	31
Trespass to the Person,	31
Negligence,	32
Obtaining Consent,	32
Summary,	32
Activity,	33
References,	34
Case Law,	34
Legislation,	35
Further Reading,	35
Websites,	35

## 4 The Ethics of Prescribing

36

*Matthew Boyd, Stephanie Bridges, and Helen Boardman*

Deontology,	36
Utilitarianism,	37
Four Principles of Bioethics,	37
Autonomy,	37
Beneficence,	37
Non-maleficence,	38
Justice,	38
Making Ethical Decisions,	38
Conscience, Codes and Law,	39
Ethics and the Individual,	40
Ethics and Professional Codes,	40
Ethics and the Law,	40
Example of an Ethical Problem in Prescribing,	41
Distributive Justice: Who Should Get What Medicine?,	41
Summary,	41
Activity,	42
Useful Websites,	42
References,	42
Further Reading,	43

**5 Prescribing in Practice****44***Dianne Bowskill and Daniel Shipley*

- Independent and Supplementary Prescribing, 44
- Supplementary Prescribing and the CMP, 45
- What Information must a CMP Include?, 45
- Should I use Independent or Supplementary Prescribing?, 45
- Prescribing in Practice, 45
- Personal Prescribing Formularies, 46
- Prescribing for Patients, 46
- Interpreting and Applying Clinical Guidelines to Prescribing, 47
  - National Guidelines, 48
  - Local Guidelines, 48
    - Local Medicines Formulary, 49
    - Patient Factors, 49
- Drugs and Driving, 49
- Communicating Prescribing Decisions within the Team, 50
- Organisations and Employers, 50
- Summary, 50
- Activity, 51
- References, 51
- Further Reading, 52
- Useful Websites, 52

**6 Public Health Issues****53***Michael Watson and Katharine Whittingham*

- What is Public Health?, 53
- Contributions to Public Health, 55
- Effective Approaches to Promoting Public Health Prescribing, 55
- Gold Standards: Health-promoting Settings, 56
- Key Priority Areas for Public Health, 57
- Making Every Contact Count, 59
- Long-Term Conditions, 59
- Healthcare-Associated Infections, 59
- Medication Errors, 59
- Summary, 60
- Activity, 60
- References, 60
- Useful Websites, 61

**SECTION 2 Pharmacology****63**

Section Introduction, 65

**7 General Principles of Pharmacology****67***Joanne Lymn and Alison Mostyn*

How Do Drugs Exert Their Effects on the Body?, 67

Target Molecules, 68

Receptors, 68

Dose–Response Curves, 70

Enzymes, 74

Carrier Proteins, 74

Ion Channels, 75

Non-Target Proteins, 75

Drug Antagonism, 75

Non-Competitive Antagonism, 75

Chemical Antagonism, 75

Pharmacokinetic Antagonism, 76

Physiological Antagonism, 76

Therapeutic Index, 76

Summary, 76

Activity, 77

Reusable Learning Objects, 78

Further Reading, 78

**8 Pharmacokinetics 1: Absorption and Distribution****79***Joanne Lymn and Alison Mostyn*

How Do Drugs Get into the Body?, 79

Cell membranes, 80

Mechanisms of Crossing Cell Membranes, 80

Drug Absorption, 84

Drug Distribution, 85

Plasma Protein Binding, 85

Volume of Distribution, 88

Summary, 89

Activity, 89

Useful Websites, 90

Reusable Learning Objects, 90

Further Reading, 91

**9 Pharmacokinetics 2: Metabolism and Excretion****92***Joanne Lymn and Alison Mostyn*

- Drug Elimination, 92
- Drug Metabolism, 92
  - Cytochrome P450 Enzyme System, 93
  - Pro-drugs, 96
  - Pharmacogenetics, 96
  - Active and Toxic Metabolites, 97
  - First-pass Metabolism and Bioavailability, 97
  - Factors Affecting Drug Metabolism, 99
- Drug Excretion, 99
  - Renal Excretion, 99
  - Factors Affecting Renal Drug Excretion, 100
  - Biliary Excretion, 101
- Drug Clearance, 102
- Half-Life, 102
- Summary, 103
- Activity, 104
- Further Reading, 105
- Useful Websites, 105
- Reusable Learning Objects, 105

**10 Routes of Administration****106***Joanne Lymn and Roger Knaggs*

- Local Versus Systemic Drug Effect, 106
- Oral Administration, 107
  - Excipients and Bulking Agents, 108
  - Factors Affecting Absorption of Orally Administered Drugs, 108
- Sublingual Administration, 109
- Rectal Administration, 109
- Transdermal Administration, 110
- Ocular Administration, 110
- Inhalation, 110
- Intramuscular Injection, 110
- Subcutaneous Injection, 111
- Intravenous Injection, 111
- Summary, 111
- Activity, 112
- Further Reading, 113

**11 Variations in Drug Handling****114***Michael Randall*

- Why is there variability?, 114
- Pharmacokinetic Variability with Age, 114
  - Neonates, 114
  - Paediatrics, 116
  - Elderly, 117
- Pharmacodynamic Variability, 118
  - Elderly, 118
  - Liver Failure, 119
  - Renal Impairment, 120
  - Pharmacogenetics, 120
- Summary, 121
- Activity, 122
- References, 123
- Further Reading, 123

**12 Polypharmacy and Medicines Optimisation****124***Daniel Shipley*

- What is Polypharmacy?, 124
- Which Patient Groups are Most Impacted?, 125
  - Older Patients and Multimorbidity, 125
  - Patients with Poor Adherence, 125
  - Patients with Learning Disabilities, Autism or a Dual Diagnosis, 126
  - During Discharge and Admission, 126
  - Patients Who Have Been Historically Under-Represented in Drug Trials, 126
- What are the Implications for Healthcare Services?, 127
- Which Drugs are Most Problematic?, 127
- Medicines Optimisation, 127
  - Principle 1: Aim to Understand the Patient's Experience, 128
  - Principle 2: Evidence-Based Choice of Medicines, 128
  - Principle 3: Ensure Medicines Use is as Safe as Possible, 129
  - Principle 4: Make Medicines Optimisation Part of Routine Practice, 129
  - Implementation strategies, 129
    - (a) Systems which Help Identify and Report Patient Safety Incidents, 129
    - (b) Communication Strategies when Transferring Patient Care, 129
    - (c) Medicines Reconciliation, 130

Medicines Optimisation Toolkits and Deprescribing, 130  
Summary, 131  
Activity, 131  
References, 132  
Guidance, 133

## **13 Adverse Drug Reactions and Interactions**

**134**

*Alison Mostyn and Daniel Shipley*

Adverse Drug Reactions: Some Definitions, 134  
Classification of ADRs, 134  
Susceptible Patient Groups, 134  
Mechanisms of ADRs and Examples, 135  
    Pharmaceutical Causes, 135  
    Pharmacokinetic Causes, 136  
    Pharmacodynamic Causes, 136  
Identification and Management of ADRs, 137  
    Yellow Card Scheme, 138  
Drug Interactions, 139  
    Pharmacokinetic Interactions, 139  
    Pharmacodynamic Interactions, 140  
Management of Interactions, 141  
Summary, 141  
Activity, 142  
Reference, 143  
Further Reading, 143  
Useful Websites, 143

## **14 Introduction to the Autonomic Nervous System**

**144**

*Joanne Lymn*

The Nervous System, 144  
The Autonomic Nervous System, 144  
Action of the Autonomic Nervous System on Body Organs, 145  
    Sympathetic Nervous System, 146  
    Parasympathetic Nervous System, 147  
Neuron Structure, 147  
Neuron Function, 147  
    Neurons in the Autonomic Nervous System, 149  
Cholinergic Transmission, 150

Noradrenergic Transmission,	152
Summary,	155
Activity,	155
Further Reading,	156

## **15 Clinical Application of the Principles of the Autonomic Nervous Systems**

**157***Joanne Lymn*

Drugs Which Target the Parasympathetic Nervous System and Cholinergic Transmission,	157
Muscarinic Agonists,	157
Muscarinic Antagonists,	159
Anticholinesterase Drugs,	160
Drugs Which Target the Sympathetic Nervous System and Noradrenergic Transmission,	160
Adrenergic Agonists,	160
Adrenergic Antagonists,	162
Drugs Affecting Noradrenaline Synthesis,	163
Drugs Affecting Noradrenaline Release,	164
Drugs Affecting Noradrenaline Uptake,	164
Summary,	164
Activity,	165
Further Reading,	166

## **16 The Gastrointestinal System**

**167***Michael Randall*

Dyspepsia,	167
Control of Gastric Acid Secretion,	168
Pharmacological Basis of Management,	169
Antacids,	169
Alginates,	169
H <sub>2</sub> -Receptor Antagonists,	169
Proton Pump Inhibitors,	170
Prostaglandin Analogues,	170
Non-Ulcer Dyspepsia,	170
Nausea and Vomiting,	171
Pharmacological Basis of Management,	171
Histamine H <sub>1</sub> -Receptor Antagonists,	172
Antimuscarinic Agents,	172

- Dopamine Receptor Antagonists, 172
- 5-Hydroxytryptamine Receptor Antagonists, 173
- Diarrhoea, 173
  - Pharmacological Basis of the Management of Diarrhoea, 173
  - Oral Rehydration Therapy, 173
  - Antibiotics, 173
  - Antimotility Agents, 174
- Constipation, 174
  - Management, 174
  - Osmotic Laxatives, 174
  - Stimulant Laxatives: Senna Extracts and Sodium Picosulphate, 174
- Summary, 175
- Activity, 175
- Reference, 176
- Further Reading, 176
- Guidance, 176

## 17 Cardiovascular Drugs and Diseases

177

*Richard Roberts*

- Regulation of Blood Pressure, 177
  - Renin-Angiotensin-Aldosterone System, 178
  - Cardiac Output and Regulation by the Autonomic Nervous System, 179
- Hypertension, 179
  - Calcium Channel Inhibitors, 180
- Drugs That Affect the RAAS, 182
  - Angiotensin-Converting Enzyme Inhibitors, 182
  - Angiotensin Receptor Antagonists (sartans), 182
- Diuretics (See Chapter 19), 183
  - Thiazides and Thiazide-Like, 183
  - Potassium-Sparing Diuretics, 184
- $\beta$ -Adrenoceptor Antagonists ( $\beta$ -Blockers), 184
- $\alpha$ -Adrenoceptor Antagonists, 185
  - Treatment of Hypercholesterolaemia, 186
  - HMG-CoA Reductase Inhibitors (statins), 186
  - Cholesterol Uptake Inhibitors, 187
  - Proprotein Convertase Subtilisin/kexin Type 9 inhibitors, 187
  - Loop Diuretics (Chapter 19), 188

Drugs Targeting the RAAS,	189
ACE inhibitors,	189
$\beta$ -Adrenoceptor Antagonists ( $\beta$ -Blockers),	189
Mineralocorticoid Receptor Antagonists,	189
Neutral Endopeptidase Inhibitors,	190
Ivabradine,	190
Sodium-Glucose Co-Transporter 2 Inhibitors,	190
Digoxin,	190
Ischaemic Heart Disease,	191
Nitrates (e.g., Glyceryl Trinitrate or Isosorbide Mononitrate),	191
$\beta$ -Adrenoceptor Antagonists ( $\beta$ -Blockers),	192
Calcium Channel Inhibitors,	192
Potassium Channel Activators,	193
If Channel Inhibitors,	193
Summary,	193
Activity,	194
References,	195
Further Reading,	195
Useful Website,	195

## 18 Haemostasis and Thrombosis

196

*Michael Randall*

Haemostasis,	196
Vasoconstriction,	196
Adhesion and Activation of Platelets,	196
Coagulation,	196
Thrombosis,	197
Arterial Thrombi,	197
Venous Thrombi,	197
Cardioembolic Thrombi,	197
Role of the Coagulation Cascade in Thrombosis and Haemostasis,	197
Anticoagulant Drugs,	199
Direct Oral Anticoagulants,	199
Pharmacokinetics,	199
Warfarin,	200
Heparins,	201
Role of Platelets in Thrombosis and Haemostasis,	202
Antiplatelet Drugs,	202
Aspirin,	202

- Adverse Effects, 202
- Fibrinolytic Cascade, 204
- Summary, 205
- Activity, 206
- References, 207
- Further Reading, 207
- Guidance, 207

## 19 The Renal System

208

*Michael Randall*

- Structure and Function of the Kidneys, 208
  - Structure of the Kidneys, 208
  - Functions of the Kidneys, 210
  - Risk Factors for Kidney Disease, 210
- The Principles of Glomerular Filtration, 210
  - Assessing Kidney Function, 211
- Drug Use in Patients with Renal Impairment, 212
  - Absorption, 213
  - Distribution, 213
  - Metabolism, 213
  - Excretion, 213
- Drug Dosing in Renal Impairment, 213
  - Examples of Drugs that May Need Dose Adjusting in Renal Impairment, 215
  - Monitoring, 216
  - Nephrotoxicity, 216
- Use of Diuretics in Renal Failure, 217
- Summary, 218
- Activity, 218
- References, 219
- Further Reading, 219
- Useful Websites, 219
- Reusable Learning Objects, 220

## 20 The Respiratory System

221

*Richard Roberts*

- The Regulation of Airway Tone, 221
- The Role of Inflammation in Respiratory Disease, 222
  - Bronchodilators, 224

β-Adrenoceptor Agonists,	224
β-Blockers and Asthma,	225
Muscarinic Receptor Antagonists,	225
Methylxanthines,	226
Anti-inflammatory Agents,	227
Corticosteroids,	227
Non-steroidal Anti-inflammatory Drugs and Asthma,	229
Cysteinylleukotriene Receptor Antagonists,	229
Phosphodiesterase Inhibitors,	230
Biologics,	231
Mucolytics and Related Compounds,	231
Guidance,	232
Summary,	232
Activity,	232
References,	233
Further Reading,	234
Clinical Guidelines,	234

## 21 Introduction to the Central Nervous System

235

*Yvonne Mbaki*

Central Nervous System,	235
Parts of the Brain,	235
The Hindbrain,	235
The Midbrain,	236
The Forebrain,	236
Neuronal Structure and Function,	236
Glial cells,	237
Anatomy and Physiology of Nerve Cells,	237
Integration of Inputs via the Dendrites,	237
Excitatory Postsynaptic Potential,	238
Inhibitory Postsynaptic Potential,	238
Action Potential Transmission,	239
Output Synapses,	239
Principal Neurotransmitters of the CNS,	239
Acetylcholine,	240
Noradrenaline,	240
Dopamine,	241
Serotonin (5-hydroxytryptamine or 5HT),	241
Gamma-amino Butyric Acid,	242

- Glutamate, 242
- Endogenous Opioids, 243
- Summary, 243
- Activity, 244
- Further Reading, 244
- Useful Website, 244

## **22 Neurodegenerative Disorders**

**245**

*David Kendall*

- Parkinson's Disease, 245
  - Epidemiology, 245
  - Clinical Features and Diagnosis, 245
  - Pathogenesis, 245
  - Genetics and Other Risk Factors, 246
  - Anti-parkinsonian Therapy, 246
  - Treatment of Motor Symptoms, 246
  - Treatment of Non-motor Symptoms, 249
  - Advanced Parkinson's Disease, 250
- Alzheimer's Disease, 250
  - Epidemiology, 250
  - Pathophysiology, 250
  - Risk Factors, 251
  - Diagnosis, 251
  - Pharmacological Interventions in AD, 252
  - Other approaches to Treatment, 253
  - Treatment of Neuropsychiatric Symptoms in AD, 253
- Summary, 254
- Activity, 254
- References, 255
- Further Reading, 255
- Useful Websites, 255

## **23 Depression and Anxiety**

**256**

*Yvonne Mbaki*

- Depression, 256
  - Monoamine Theory of Depression, 257
  - Antidepressant Drugs, 257
- Anxiety Disorders, 260
  - Anxiolytic Therapy, 261

Summary,	264
Activity,	264
References,	265
Further Reading,	266
Clinical Guidelines,	266

## **24** Schizophrenia

**267**

*David Kendall*

Description and Epidemiology,	267
Aetiology of Schizophrenia,	268
Genetic Factors,	268
Other Risk Factors,	269
Pathogenesis of Schizophrenia,	269
The Dopamine Hypothesis,	269
The Glutamate Hypothesis,	270
The Serotonin Hypothesis,	270
Treatment of Schizophrenia,	270
First-Generation (Typical) Antipsychotics,	270
Second-Generation (Atypical) Antipsychotics,	272
Choice of Antipsychotic Treatment,	273
Other Uses of Antipsychotic Medicines,	274
Summary,	274
Activity,	275
References,	275
Further Reading,	276
Useful Websites,	276

## **25** Epilepsy and Antiseizure Drugs

**277**

*Michael F O'Donoghue and Christina Giavasi*

Introduction and Definitions,	277
Seizure Types and Epilepsies,	278
Common Antiseizure Medications: Mechanisms and Use,	279
Practice Applications with Common Scenarios,	281
New Epilepsy,	281
Follow-up Visits,	282
Emergency Hospital Admissions,	286
Special Groups,	286
Women with Epilepsy,	286

Epilepsy in the Older Person,	287
People with Intellectual Disability,	288
Young People in Transition from Paediatrics,	288
Holistic Care,	288
Summary,	289
Activity,	289
Useful Websites,	291
References,	291
Clinical Guidelines,	292

## 26 Pain and Analgesia

293

*Roger Knaggs*

What is Pain?,	293
Pain Physiology,	294
Pain Detection,	294
Pain Transmission,	296
Pain Perception,	297
Analgesic Pharmacology,	298
Paracetamol,	298
Non-steroidal Anti-inflammatory Drugs,	299
COX-2 Selective Drugs,	301
Opioids,	302
Mechanism of Action,	302
Other Analgesics,	304
World Health Organization Pain Ladder,	304
Guidance,	305
Summary,	305
Activity,	306
References,	306
Useful Websites,	307
Clinical Guidance,	307
Further Reading,	307

## 27 Drugs of Misuse

308

*Michael Randall*

Classification of Drugs of Misuse,	308
Addiction, Dependence and Tolerance,	309
Cannabinoids,	309

Opioids,	309
Cocaine,	310
Ketamine,	310
Lysergic Acid Diethylamide,	310
Amphetamines,	310
‘Ecstasy’, 3,4-Methylenedioxy Methamphetamine,	310
Some other Therapeutic Drugs Subject to Potential Abuse,	310
Alcohol,	310
Nicotine,	311
Performance-enhancing Drugs,	311
Treatment of Drug Addiction,	311
Support for Opioid Abuse,	311
Nicotine Therapy,	312
Alcohol Dependence,	312
Summary,	312
Activity,	312
References,	313
Further Reading,	313
Clinical Guidelines,	314
Useful Websites,	314

## **28** **Antibacterial Chemotherapy**

**315**

*Tim Hills*

General Principles of Antimicrobial Chemotherapy,	315
Bacterial Classification,	315
Antibiotics: Key Descriptions,	318
Mechanism of Action of Antibacterial Drugs,	319
Inhibition of Cell Wall Synthesis,	319
Inhibition of Bacterial Protein Synthesis,	324
Inhibition of Bacterial DNA synthesis,	326
Inhibition of Folate Synthesis,	327
Summary,	328
Activity,	329
References,	330
Further Reading,	330
Useful Websites,	330
Reusable Learning Objects,	330

**29 Antibiotic Resistance and *Clostridioides Difficile* 331***Tim Hills*

- Bacteria and the Human Body, 331
- Antibiotic Resistance, 333
  - Native Resistance, 333
  - Resistance Acquired Following Mutation, 333
  - Mechanisms of Resistance, 334
  - Multiresistant Bacteria, 335
- Antibiotic-Associated Diarrhoea and *Clostridioides Difficile*, 336
  - Treatment of *Clostridioides Difficile* Infection, 336
  - Vancomycin, 336
  - Metronidazole, 337
  - Fidaxomicin, 337
  - Modulation of CDI Risk, 337
- Summary, 339
- Activity, 339
- References, 340
- Further Reading, 341

**30 Antifungal and Antiviral Drugs 342***Tim Hills*

- Mycology and Classification, 342
  - Pathogenic Moulds, 342
  - Pathogenic Yeasts, 343
- Antifungal Drugs, 343
  - Cell Wall Active Drugs, 343
- Viruses, 346
  - Anti-Herpes Virus Drugs, 346
  - Anti-Influenza Virus Drugs, 347
  - SARS-CoV-2/COVID-19, 349
- Summary, 350
- Activity, 350
- References, 351
- Useful Websites, 351
- Further Reading, 351

**31 The Endocrine System****352***Alison Mostyn and Daniel Shipley*

- The Endocrine System, 352
- Mechanisms of Hormone Action, 352
- Glucose Homeostasis and Diabetes Mellitus, 354
  - The Endocrine Pancreas, 354
  - Endocrine (peripheral) Effects of Insulin, 356
  - Paracrine Effects of Insulin, 356
  - Cellular Actions of Insulin, 356
- Diabetes Mellitus, 357
- Treatment of Diabetes, 358
  - Insulin, 358
  - Insulin Prescribing Principles, 359
- Type 2 Diabetes Management, 360
  - Oral Antidiabetic Agents, 360
  - GLP-1 Mimetics (Incretin Mimetics), 363
- The Thyroid Gland, 363
  - Thyroid Function, 363
- Hypothyroidism, 364
- Hyperthyroidism, 365
- Summary, 366
- Activity, 366
- References, 367
- Further Reading, 367
- Useful Website, 368
- Clinical Guidance, 368

**32 Contraception and Reproductive Health****369***Alison Mostyn and Anna Soames*

- Endocrine Regulation of the Female Reproductive System, 369
- Mechanism of Action of Oestrogen and Progesterone, 371
- Formulations of Oestrogens and Progesterones, 372
- Hormonal Contraception, 372
- Combined Hormonal Contraception and the Progestogen-only Pill, 373
  - Combined Hormonal Contraception, 373

Progesterone-only Pills,	374
Progesterone-only Injection,	375
Drug Interactions,	375
Absorption,	375
Metabolism,	375
Enzyme Inhibition and Induction,	376
Oestrogen's Effects on Co-administered Drugs,	376
Emergency Contraception,	377
Non-contraceptive uses of Oestrogen and Progesterone,	378
Hormone Replacement Therapy,	378
Summary,	378
Activity,	378
References,	379
Further Reading,	379
Useful Websites,	379
Clinical Guidance,	380

## 33 Cancer Pharmacotherapy

381

*Michael Randall*

Cancers,	381
Cancer Pharmacotherapy,	382
Cytotoxic Anticancer Chemotherapy,	382
Antimetabolites,	382
Folate Antagonists (e.g. Methotrexate),	382
Pyrimidine Analogues (e.g., 5-fluorouracil, Capecitabine, Gemcitabine),	383
Purine Analogues (e.g., Mercaptopurine and Thioguanine),	384
Alkylating Agents (e.g., Cyclophosphamide, Busulphan),	384
Platinum Compounds (e.g., Cisplatin),	384
Anthracycline Antibiotics (e.g., Doxorubicin, Epirubicin and Daunorubicin),	384
Topoisomerase Inhibitors (e.g., Etoposide),	384
Microtubule Inhibitors,	384
Side Effects of Cytotoxic Anticancer Drugs,	384
Myelosuppression,	385
Regimens,	386
Targeted Cancer Therapy,	386
Hormonal-based Therapies,	386
Human Epidermal Growth Factor Receptor 2,	386

EGF Receptor Kinase,	387
Tyrosine Kinase Inhibitors,	387
Poly (Adenosine Diphosphate-Ribose) Polymerase (PARP) Inhibitors (Olaparib),	387
Programmed Death-1 Receptor Inhibitors,	388
Proteasome Inhibitors,	389
Anti-Angiogenic Approaches,	389
Guidance,	389
Practice Points,	389
Summary,	389
Activity,	390
Useful Websites,	391
Further Reading,	391

## 34 Musculoskeletal Disease

392

*Sana Awan and David Andrew Walsh*

Rheumatic and Musculoskeletal Disorders,	392
Overview of Prevalent RMDs,	393
Osteoarthritis,	393
Inflammatory Arthritis,	394
Spinal Pain,	395
Gout and Pseudogout,	395
Fibromyalgia and Nociceptive Pain,	397
Pharmacological Management of Inflammatory Arthritis,	397
Symptom Control in Inflammatory Arthritis,	397
Inflammatory Arthritis Disease Suppression and Remission,	398
Screening and Counselling Prior to DMARD Initiation,	400
Monitoring for DMARD Benefits and Risks,	401
DMARDs Commonly Prescribed for Inflammatory Arthritis,	403
Biologic and Targeted Synthetic DMARDs,	404
Summary,	405
Activity,	405
References,	407
Useful Websites,	408

**Glossary** **409**

**Activity Answers** **417**

**Index** **445**